Wuxi Pharmatech Inc., of Shanghai, said its toxicology facility in Suzhou, China, recently passed a surveillance good laboratory practice inspection by the FDA with no major observations. This was the first such inspection in the facility's five years of operation. The inspection was extensive, lasting five days and included the review of numerous processes and the audit of four studies, the company said.